Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
KAIO (KAIO) fluctuated by 45.9% in 24 hours: driven by TGE launch and listings on Coinbase and other exchanges

KAIO (KAIO) fluctuated by 45.9% in 24 hours: driven by TGE launch and listings on Coinbase and other exchanges

Bitget PulseBitget Pulse2026/05/08 16:02
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, the price of KAIO rose from a low of $0.125409 to a high of $0.183001, with the current price at $0.1368, marking a fluctuation amplitude of 45.9%. The 24-hour trading volume is approximately $24–32 million, indicating intense market sentiment volatility accompanied by high liquidity injection.

Brief Analysis of Causes for the Price Movement

• Official TGE Launch: On May 6, KAIO completed its TGE, with trading going live at 13:00 UTC. Multi-chain deployment (over 10 chains) led to TVL exceeding $100 million, fueling the initial pump.

• Listings on Multiple Exchanges: KAIO spot trading was listed on Bitget Launchpool (May 6–13), Gate.io, KCEX, BingX, and others. On May 7, Coinbase introduced KAIO/USD spot and perpetual contracts, further amplifying trading volume and price volatility.

Market Views and Outlook

The dominant sentiment in the community is positive, considering KAIO a leader in RWA infrastructure, highlighting that institutional funds such as BlackRock and Brevan Howard have brought TVL above $100 million. Post-TGE, strong buying is seen defending the price bottom. Discussions on X focus on the “RWA season” and governance utility, but caution against high volatility risk. Analysts predict that if liquidity persists in the short term, KAIO may maintain a $0.14–0.20 range, with attention needed on potential sell pressure after listings.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23